TOKYO and WOODCLIFF LAKE, N.J., Feb. 1 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) and Eisai's U.S. subsidiary, Eisai Corporation of North America (Headquarters: New Jersey, the United States, Chairman & CEO: Hajime Shimizu), today announced a change in the schedule for submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for E7389 (generic name: eribulin mesylate) for third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine.
Eisai is committed to developing E7389 as a potential treatment for patients with advanced breast cancer. In a Phase II study of 299 patients with advanced breast cancer who had been heavily pretreated, the compound has shown promising anti-tumor activity, with a response rate of 14.1% by investigator evaluation and 9.3% by independent radiologist evaluation. It has also been shown in the Phase II study to be generally well-tolerated, with the most common Grades 3 and 4 drug-related adverse events being 54% in neutropenia and 14% in leucopenia. Grade 3 peripheral neuropathy occurred in 6% of study participants, and there were no Grade 4 events.
Eisai had planned to submit an NDA under Subpart H*, based on Phase II
clinical trial data, to seek accelerated approval for E7389 as a third-line
breast cancer treatment (monotherapy), but is precluded from doing so,
because FDA approved another drug for this specific indication last
October. Eisai remains committed to advancing two Phase III clinical trials
for E7389, which are ongoing in the U.S. and in Europe, Study 301 for
second-line and Study 305 for third-line breast cancer treatment. Eisai now
plans to submit an NDA to FDA with data from these trials and Phase II
clinical trial data in fiscal year 2009-2010. In addition, Eisai continues
to evaluate E7389 as a potential treatment for a variety of other solid
tumors, including non-small
|SOURCE Eisai Corporation of North America|
Copyright©2008 PR Newswire.
All rights reserved